Nurix Therapeutics
Price & Volume
Stats
See more52W Range | $8.19-$27.35 |
Market Cap | $2.8B |
Shares Short | 18M |
Financials
See moreRevenue (12 Mos) | $36.7M |
Revenue Growth (YoY) | -79.5% |
Gross Profit (12 Mos) | -$304.1M |
Diluted EPS | -$3.44 |
News
See moreYahoo Finance • 11 days ago
Nurix Therapeutics (NRIX) Lands $10 Million Milestone As Phase 3 Trial Begins
Yahoo Finance • 12 days ago
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
Yahoo Finance • 12 days ago
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Yahoo Finance • 25 days ago
Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront
About
CEO | Dr. Arthur T. Sands M.D., Ph.D. |
Address | 1600 Sierra Point Parkway, Brisbane, CA, United States, 94005 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 317 |